| Budget Amount *help |
¥113,360,000 (Direct Cost: ¥87,200,000、Indirect Cost: ¥26,160,000)
Fiscal Year 2018: ¥20,800,000 (Direct Cost: ¥16,000,000、Indirect Cost: ¥4,800,000)
Fiscal Year 2017: ¥20,800,000 (Direct Cost: ¥16,000,000、Indirect Cost: ¥4,800,000)
Fiscal Year 2016: ¥20,930,000 (Direct Cost: ¥16,100,000、Indirect Cost: ¥4,830,000)
Fiscal Year 2015: ¥20,800,000 (Direct Cost: ¥16,000,000、Indirect Cost: ¥4,800,000)
Fiscal Year 2014: ¥30,030,000 (Direct Cost: ¥23,100,000、Indirect Cost: ¥6,930,000)
|
|---|
| Outline of Final Research Achievements |
Aims of this project are to develop biomarkers and to establish diagnostic procedures for brain protein aging. During past 5 years, rTg4510 transgenic (tg) mice expressing P301L mutated tau and non-tg mice were examined with brain MRI and PET imaging. PET studies with [11C]PBB3 and [11C]AC-5216 tracers, which labeled tau pathology and TSPO, revealed age-dependent increases, and correlated with age-dependent volume reduction in the forebrain on MRI. Histochemical analyses confirmed the relevance of pathological tau accumulation and elevated TSPO immunoreactivity in putative microglia. Our results indicate that in vivo imaging of animal models is able to explore the temporospatial relationship among tau deposition, neuroinflammation and neuronal loss. Non-invasive PET imaging combined with transgenic mouse models can be a powerful experimental tool to investigate mechanisms of neurodegenerative diseases and evaluate therapeutic interventions.
|
